Business Wire

Patient Safety Movement Announces 69,519 Lives Saved

Del

The Patient Safety Movement Foundation (PSMF) announced today, at the 5th Annual Patient Safety, Science & Technology Summit, that 69,519 lives were saved in 2016, thanks to the efforts of more than 3526 hospitals committing to patient safety and the 70 healthcare technology companies who have signed an open data pledge.

During his keynote address on the first day of the Summit, former Vice President Joe Biden noted the importance of being “unwilling to postpone” the fight to achieve zero preventable deaths by 2020. As he stated, “We cannot spend billions on sublime new therapies to save lives from cancer, only to lose them tragically as a consequence of predictable mistakes.”

Joe Kiani, Founder of the Patient Safety Movement, spoke of the progress made during 2016: “By January 2016 we announced 24,643 lives were saved, and we made the goal to reach 50,000 lives saved by this year. As of February 2017, we've more than doubled that number.”

During today’s proceedings, there was an exclusive screening of the documentary Clean Hands. Clean Hands tells the story of Professor Didier Pittet’s 20-year campaign to promote hand hygiene as a means of preventing nosocomial infections, which are estimated to kill 16 million people worldwide each year. Professor Pittet is an ambassador to the World Health Organization and a speaker at this year’s Summit.

Also taking place today was a panel discussion on the first of three new Actionable Patient Safety Solutions (APSS) introduced at this year’s event, regarding venous thromboembolism (VTE). The Centers for Disease Control (CDC) estimates that as many as 70% of hospital-acquired cases of VTE are preventable, making the need for hospitals to improve awareness and develop new processes acute. The panel, moderated by Mike Durkin, the British National Health Service’s Director of Patient Safety, discussed the challenges surrounding VTE prevention.

Honored at the first day of the Summit were those who have made the greatest contributions in 2016 toward achieving the PSMF’s goal of zero preventable patient deaths by 2020. The 2016 Humanitarian Awards recognized the lifesaving achievements of the following leaders in patient safety:

Patrick H. Conway, MD, MSc

As the Centers for Medicare and Medicaid Services (CMS) Acting Principal Deputy Administrator and Chief Medical Officer, Dr. Conway oversees vital programs that serve the more than 130 million Americans who receive health care services through Medicare, Medicaid, the Children’s Health Insurance Program, and the Health Insurance Marketplace. He and his team work to improve quality, affordability, access, and health outcomes. In 2014, Dr. Conway was elected to the National Academy of Medicine Institute of Medicine (IOM), one of the highest honors in the fields of health and medicine. Dr. Conway, in receiving the award said, "I am honored and humbled to receive the patient safety movement humanitarian award. I look forward to continuing to help improve patient safety across the nation."

Dr. Dave Mayer, MD

Dr. Mayer is Vice President of Quality and Safety for MedStar Health, the largest healthcare provider in the mid-Atlantic region. He oversees the infrastructure for clinical quality and its operational efficiency and designs, and directs system-wide activity for patient safety and risk-reduction programs. Under Mayer, MedStar has been at the vanguard of embracing transparency in communications with patients and families when something goes wrong in treatment. Recently, MedStar worked with the US Agency for Healthcare Research and Quality (AHRQ) to develop and pilot a toolkit for their Communication and Optimal Resolution (CANDOR) program. In receiving the award, Dr. Mayer said, “It’s an amazing honor to be recognized by Joe Kiani and the Patient Safety Movement, to be honored with other recipients who have worked so hard to reduce medical harm. I am humbled to be included with such a wonderful group.”

Annamarie Saarinen

Ms. Saarinen is the CEO of the Newborn Foundation. She has been recognized by the Patient Safety Movement for spearheading the national effort to ensure all newborns are screened for the most prevalent birth defect, critical congenital heart disease (CCHD), which afflicts one in every 100 newborns. The Newborn Foundation is the first national organization focused on leveraging health, medtech, and biotechnology to improve outcomes and reduce disparities specifically for newborns. Through her work, 99% of babies are now screened for CCHD in the US every year. In receiving the award, Ms. Saarinen noted, “I am surprised and humbled to receive the Humanitarian award from the Patient Safety Movement Foundation. I am grateful for the work Dr. Granelli has done in heart disease which has created a strong platform for the Newborn Foundation to help improve and save the lives of babies. It has been an incredible opportunity to work with the Patient Safety Movement and the other advocates toward this end.”

Dr. Anne de-Wahl Granelli, PhD, MBA

Dr. Granelli has spent the last decade researching CCHD screening and it is because of her work that organizations like Annamarie Saarinen's, the Newborn Foundation, have been able to successfully create policies across the US and the world to ensure that babies don’t leave the hospital without being screened. Dr. Granelli received the award in conjunction with Annamarie to show the great work that has been accomplished in 2016 through continued research. Dr. Granelli said, “I am so honored to be a recipient of the Humanitarian award. It is truly amazing. It has also been a privilege to work with Annamarie Saarinen, and to have such an impact on the lives of babies with critical congenital heart disease.”

About the Patient Safety Movement Foundation

More than 200,000 people die every year in U.S. hospitals and 3 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare, to reduce that number of preventable deaths to 0 by 2020 (0X2020). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems and solutions of patient safety. The Foundation also convenes Patient Safety, Science and Technology summits. The Summits bring together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact recipes to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data for whom their products are purchased, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, Patient Safety Movement is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.

@0X2020 #patientsafety #0X2020

Contact information

Patient Safety Movement Foundation
Irene Paigah, 858-859-7001
irene@paigah.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future19.7.2018 15:32Pressemelding

NEORIS, a global digital consulting services company, announced today it is consolidating the most innovative solutions it has developed in different geographies and allocating unprecedented resources to deploy a network of Innovation Labs worldwide. The main objective is to lay the foundation for the continuous development of disruptive solutions for its four core industries: Manufacturing, Financial Services, Healthcare and Telecommunications. Due to its disruptive nature, NEORIS decided that its first Innovation Lab should be housed in the Monterrey Digital Hub, which today is the first-of-its-kind as it is a space where entrepreneurs, companies, universities and investors converge to foster an ecosystem for Digital Transformation. The lab inaugurated in Monterrey, Mexico is the first of a series of Innovation Labs that will open in the different countries that NEORIS operates, and is a space where customers can experience emerging technologies through real-life scenarios. One such

CORRECTING and REPLACING Albar Capital Deploys FlexNOW19.7.2018 15:29Pressemelding

Subhead of release should read: Out-of-the-Box Multi-Asset Execution Management System (instead of Easy-to-Install Multi-Asset Execution Management System). The corrected release reads: ALBAR CAPITAL DEPLOYS FLEXNOW Out-of-the-Box Multi-Asset Execution Management System FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk managemen

Full Core of Westinghouse Fuel Achieved at South-Ukraine Nuclear Power Plant Unit 319.7.2018 13:25Pressemelding

Westinghouse Electric Company announced today that Ukraine’s State Enterprise National Nuclear Energy Generation Company (SE NNEGC) Energoatom’s South-Ukraine NPP Unit 3 near Yuzhnoukrainsk in Mykolaiv province was loaded with a full core of Westinghouse VVER-1000 fuel. This is the first unit in Ukraine to operate with Westinghouse VVER-1000 fuel assemblies as the sole fuel source. “Westinghouse began supplying fuel to Ukraine in 2005, when the first lead test assemblies were delivered to South-Ukraine Unit 3,” said Aziz Dag, vice president and managing director, Northern Europe. “We are proud to continue supporting Ukraine with their energy diversification by supplying a full core of Westinghouse VVER-1000 fuel to our customer, Energoatom.” Westinghouse currently supplies fuel to six of Ukraine’s 15 nuclear power reactors. Beginning in 2021, the number of reactors with Westinghouse fuel will increase to seven. “Westinghouse has made significant investments over the last several years

Seoul Semiconductor Delivers Its Innovative LED "SunLike" to U.S. Lighting Market19.7.2018 13:00Pressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a market leader in LED (light emitting diode) design and manufacturing, announced that its innovative LED “SunLike” is applied to brand new lightings to be launched by three lighting premium brands in U.S., Pure Edge Lighting, LEDRAbrands, Inc. and Elite Lighting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005377/en/ The product of LEDRAbrands, Inc., NU4RA-SUN, which applied SunLike of Seoul Semiconductor (Photo: Business Wire) Seoul Semiconductor supplies SunLike to pendant lighting for Pure Edge, a U.S. lighting solution company. It is applied to high-end lighting for museums and art galleries that require the highest color quality. The leading lighting design companies, LEDRAbrands, Inc. and Elite Lighting, apply SunLike to downlights and spotlights respectively. “We have selected Seoul Semiconductor’s innovative LED SunLike for our human centric lighting and believ

Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors19.7.2018 12:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers. Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain regulatory milestones. In addition, Kite will make an upfront purchase of equity in Gadeta from Gadeta’s shareholders and may acquire additional equity in Gadeta upon achievement of certain R&D milestones. Kite will have the exclusive option to acquire Gadeta. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005418/en/ Gadeta has developed a proprietary technology to engineer alpha beta T cells with gamma delta TCRs, called TEGs, for

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint19.7.2018 12:08Pressemelding

CARMELINA®1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta® (linagliptin) demonstrating similar cardiovascular safety compared to placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today positive top-line results, which evaluated the impact of treatment with linagliptin vs. placebo on cardiovascular safety on top of standard of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005409/en/ The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for cardiovascular disease. The overall safety profile of linagliptin in CARMELINA®, including adults